The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II, open-label study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma.
 
Renuka V. Iyer
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Exelixis; Incyte; Lexicon; Merck; Novartis
Research Funding - Cleveland BioLabs (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Daneng Li
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech; Ipsen; Lexicon; Taiho Pharmaceutical
Speakers' Bureau - Advanced Accelerator Applications; Eisai; Exelixis; Ipsen; Lexicon
Research Funding - Brooklyn ImmunoTherapeutics (Inst)
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - Array BioPharma; Eisai; Exelixis; Genentech/Roche
Speakers' Bureau - Amgen; Eisai; Exelixis; Genentech/Roche; ipsen; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
 
Michael N. Needle
Employment - AVEO
Leadership - AVEO
Stock and Other Ownership Interests - AVEO
 
Thomas Adam Abrams
Stock and Other Ownership Interests - Guardant Health; InVitae; Jounce Therapeutics
Consulting or Advisory Role - Aduro Biotech; Bayer; Bristol-Myers Squibb; Eisai; Exelixis/Ipsen; Kaleido Biosciences; Merck
Research Funding - Lilly
Expert Testimony - Genentech